A genome-wide linkage and association scan reveals novel loci for autism. by Weiss, Lauren A et al.
UCLA
UCLA Previously Published Works
Title
A genome-wide linkage and association scan reveals novel loci for autism.
Permalink
https://escholarship.org/uc/item/3719t9v1
Journal
Nature, 461(7265)
ISSN
0028-0836
Authors
Weiss, Lauren A
Arking, Dan E
Gene Discovery Project of Johns Hopkins & the Autism Consortium
et al.
Publication Date
2009-10-01
DOI
10.1038/nature08490
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
A GENOME-WIDE LINKAGE AND ASSOCIATION SCAN 
REVEALS NOVEL LOCI FOR AUTISM
Lauren A. Weiss*, Dan E. Arking*, and The Gene Discovery Project of Johns Hopkins the 
Autism Consortium**
Summary
Although autism is a highly heritable neurodevelopmental disorder, attempts to identify specific 
susceptibility genes have thus far met with limited success 1. Genome-wide association studies 
(GWAS) using half a million or more markers, particularly those with very large sample sizes 
achieved through meta-analysis, have shown great success in mapping genes for other complex 
genetic traits (http://www.genome.gov/26525384). Consequently, we initiated a linkage and 
association mapping study using half a million genome-wide SNPs in a common set of 1,031 
multiplex autism families (1,553 affected offspring). We identified regions of suggestive and 
significant linkage on chromosomes 6q27 and 20p13, respectively. Initial analysis did not yield 
genome-wide significant associations; however, genotyping of top hits in additional families 
revealed a SNP on chromosome 5p15 (between SEMA5A and TAS2R1) that was significantly 
associated with autism (P = 2 × 10−7). We also demonstrated that expression of SEMA5A is 
reduced in brains from autistic patients, further implicating SEMA5A as an autism susceptibility 
gene. The linkage regions reported here provide targets for rare variation screening while the 
discovery of a single novel association demonstrates the action of common variants.
For a high-resolution genetic study of autism, we selected families with multiple affected 
individuals (multiplex) from the widely studied Autism Genetic Resource Exchange 
(AGRE) and US National Institute for Mental Health (NIMH) repositories (Supplementary 
Methods, Supplementary Table 1). Although the phenotypic heterogeneity in autism 
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spectrum disorders is extensive, in our primary screen we selected families in which at least 
one proband met ADI-R criteria for diagnosis of autism and included additional siblings in 
the same nuclear family affected with any autism spectrum disorder. We previously reported 
an early copy number analysis that revealed a significant role for microdeletion and 
duplication of 16p11.2 in ASD causation 2; here, we present extensive genome-wide linkage 
and association analyses performed with this high density of SNPs and identify independent 
and novel genome-wide significant results by both linkage and association analyses.
A PUBLIC AUTISM DATASET
We combined families and samples from two sources for the primary genetic association 
screen. The AGRE sample included nearly 3,000 individuals from over 780 multiplex 
autism families in the AGRE collection 3 genotyped at the Broad Institute on the Affymetrix 
5.0 platform, which includes over 500,000 SNPs. The NIMH sample included a total of 
1,233 individuals from 341 multiplex nuclear families (258 of which were independent of 
the AGRE sample) genotyped at the Johns Hopkins Center for Complex Disease Genomics 
on Affymetrix 5.0 and 500K platforms, including the same SNP markers as were genotyped 
in the AGRE sample.
Before merging, we carefully filtered each data set separately to ensure the highest possible 
genotype quality for analysis, since technical genotyping artifacts can create false positive 
findings. We therefore examined the distribution of χ2 values for the highest quality data, 
and used a series of quality control (QC) filters designed to identify a robust set of SNPs, 
including data completeness for each SNP, Mendelian errors per SNP and per family, and a 
careful evaluation of inflation of association statistics as a function of allele frequency and 
missing data (see Methods). As 324 individuals were genotyped at both centers, we 
performed a concordance check to validate our approach. After excluding one sample mix-
up, we obtained an overall genotype concordance between the two centers of 99.7% for 
samples typed on 500K at JHU and 5.0 at Broad and 99.9% for samples run on 5.0 arrays at 
both sites. The combined dataset, consisting of 1,031 nuclear families (856 with two 
parents) and a total of 1,553 affected offspring, was employed for genetic analyses 
(Supplementary Table 1). These data were publicly released in October, 2007 and are 
directly available from AGRE and NIMH.
For linkage analyses, the common AGRE/NIMH dataset was further merged with Illumina 
550K genotype data generated at the Children’s Hospital of Philadelphia (CHOP) and 
available from AGRE, adding ~300 nuclear families (1,499 samples). We used the extensive 
overlap of samples between the AGRE/NIMH and the CHOP datasets (2,282 samples) to 
select an extremely high quality set of SNPs for linkage analysis. Specifically, we only 
included SNPs genotyped in both datasets with >99.5% concordance and ≤1 Mendelian 
error.
LINKAGE ANALYSIS
Linkage analysis involving high densities of markers, where clusters of markers are in 
linkage disequilibrium (LD), can falsely inflate the evidence for genetic sharing among 
siblings when neither parent is genotyped 4. To alleviate these concerns, we analyzed a 
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pruned set of 16,311 highly polymorphic, high-quality autosomal SNPs which were filtered 
to remove any instances in which two nearby markers were correlated with r2>0.1, 
providing a marker density of ~0.25cM (see Methods). In this analysis of 878 families, four 
genomic regions showed LOD scores in excess of 2.0 and one region, 20p13, exceeded the 
formal genome-wide significance threshold of 3.6 5 (maximum LOD, 3.81; Figure 1a, 
Supplementary Table 2). Restricting analysis to only those families with both parents 
genotyped (784 families) showed that these results are not an artifact of missing parental 
data (Figure 1b). We further tested the stability of these results by varying the recombination 
map and halving the marker density by placing every other marker into two non-overlapping 
SNP sets (Methods Summary); all analyses showed consistent and strong linkage to the 
same regions (data not shown).
FAMILY-BASED ASSOCIATION ANALYSIS
We used the transmission disequilibrium test (TDT) across all SNPs passing quality control 
in the complete family dataset for association analyses since the TDT is not biased by 
population stratification. We estimated a threshold for genome-wide significance using both 
permutation (P < 2.5 × 10−7) and estimating the effective number of tests (P < 3.4 × 10−7) 
and use the more conservative, here (see Methods). No SNP met criteria for genome-wide 
significance at P < 2.5 × 10−7. However, we observed an excess of independent regions 
associated at P < 10−5 (6 observed vs. 1 expected) and P < 10−4 (30 observed vs. 15 
expected) despite the lack of overall statistical inflation (λ = 1.03, Supplementary Figure 1), 
suggesting that common variants in autism exist, but that our initial scan did not have 
sufficient statistical power to identify them definitively (Supplementary Figure 2, Table 1).
For the TDT associations with P < 10−4, we additionally utilized the cases that were 
excluded from the TDT due to missing parental data. We matched 90 independent and 
unrelated cases with 1,476 NIMH control samples genotyped on the Affymetrix 500K arrays 
6, and performed case-control association analysis (Supplementary Table 3), combining 
these results with the TDT data. Promisingly, we now observed 8 SNPs (in 7 independent 
regions) with association at P < 10−5(Table 1). Of note, comparing Caucasian with non-
Caucasian samples in the AGRE/NIMH dataset, we did not observe significant 
heterogeneity for top results.
Our strongest associations were at chromosome 4q13 (rs17088254, P = 8.5 × 10−6) between 
CENPC1, a centromere autoantigen, and EPHA5, an ephrin receptor potentially involved in 
neurodevelopment; at 5p15 (rs10513025, P = 1.7 × 10−6) in the EST DB512398, located 
between SEMA5A and TAS2R1; at 6p23 (rs7766973, P = 6.8 × 10−7) in JARID2, an ortholog 
of the mouse jumonji gene, encoding a nuclear protein essential for embryogenesis, 
especially neural tube formation; at 9p24 (rs4742409, P = 7.9 × 10−6) between PTPRD, a 
protein tyrosine phosphatase involved in neurite outgrowth, and JMJD2C, a jumonji-domain 
containing protein involved in tri-methyl specific demethylation; at 9q21 (rs952834, P = 7.8 
× 10−6) between ZCCHC6, a zinc finger and CCHC domain containing protein, and GAS1, 
growth arrest specific protein; at 10q21 (rs7923367, P = 3.4 × 10−6) in CTNNA3, alpha 3 
catenin, which may be involved in the formation of stretch-resistant cell-cell adhesion 
complexes; and two SNPs on 11p14 (rs12293188, P = 1.1 × 10−6; rs16910194, P = 3.7 × 
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10−6) in GAS2, a caspase-3 substrate that plays a role in regulating microfilament and cell 
shape changes during apoptosis and can modulate cell susceptibility to p53-dependent 
apoptosis by inhibiting calpain activity (Table 1).
REPLICATION STUDIES
To confirm whether any of these top results might indicate true susceptibility loci, we 
attempted to replicate these signals, as well as others with P < 10−4 in the initial TDT that 
met stringent genotyping quality criteria (Supplementary Table 3). We used several data 
sources to replicate the association results. First, we utilized additional autism family 
samples (318 trios collected by investigators of the Autism Consortium and in Montreal) 
with genome-wide Affymetrix 5.0/500K array data also genotyped at the Genetic Analysis 
Platform of the Broad Institute using the same conditions, QC, and analysis pipelines 
(Methods).
Second, independent Autism Genome Project (AGP) families, along with a set of Finnish 
families and a set of Iranian trios were used for replication of our top findings (n=1,755 
trios). Two Sequenom replication pools were designed, attempting to include as many of the 
regions associated at P < 10−4 as possible. The full set of SNPs considered and those 
successfully genotyped are shown in Supplementary Table 3, with linkage disequilibrium 
(r2) noted for SNPs selected as proxies for Affymetrix markers. One of the eight SNPs with 
P < 10−5 (rs10513025) that failed in this Sequenom assay was subsequently replaced in a 
subset of AGP samples with a TaqMan assay. This assay showed 99.89% concordance with 
Affymetrix genotypes in the overlapping AGRE-NIMH samples (2,797/2,800 concordant 
genotypes), with manual review of the Affymetrix genotype calls also confirming the 
marker to be of extremely high quality (Supplementary Figure 4). In the independent 
replication effort, only rs10513025 was associated with P < 0.01 (Table 1).
Combining the scan and replication data, only rs10513025 met criteria for genome-wide 
significance defined by LD and permutation analyses (P < 2.5 × 10−7). To increase coverage 
of this region and fill in missing genotypes and SNPs that failed quality control, we 
performed imputation analysis. rs10513026 was highly (but not perfectly) correlated to the 
replicated chromosome 5 SNP (rs10513025) and showed even stronger association than 
originally observed with rs10513025 (Supplementary Figure 3). These and several other 
promising SNPs were directly genotyped in the original scan samples and, in fact, showed 
higher levels of significance (Table 2). Direct genotyping confirmed that rs10513026 
showed stronger association than rs10513025 (P-value 4.5 × 10−6 vs. 9.8 × 10−6 in the re-
genotyped scan trios), increasing the significance of this observation further. Several other 
promising results from this analysis were genotyped in a subset of scan samples, and, of 
note, the top SNP in imputation analysis (rs10874241, imputation P = 9.8 × 10−7, OR = 
0.43) showed consistent results (OR = 0.4, P = 4 × 10−7) when directly genotyped 
(Supplementary Table 4).
rs10513025 and neighbors are on chromosome 5p15 in a region of LD containing several 
other ESTs and TAS2R1, a bitter taste receptor (Supplementary Figure 3). The SNPs are ~80 
kb upstream of semaphorin 5A (SEMA5A), a gene implicated in axonal guidance and known 
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to be down-regulated in lymphoblastoid cell lines of autism cases versus healthy controls 7. 
An independent study at Children’s Hospital Boston using whole blood (SWK, LK, ZK, 
manuscript in preparation) confirms this lower expression (P = 0.0034) of SEMA5A in 
autism cases versus controls. To more completely evaluate the role of this locus in autism 
pathogenesis, we evaluated the entirety of 5p15 for copy-number variation. Despite 
excellent probe coverage throughout the locus, no common or rare copy number variants 
were detected in the entire AGRE scan in the region of LD surrounding the associated SNPs 
and the entire SEMA5A locus including 250 kb up and downstream (see Methods).
SEMA5A EXPRESSION IN AUTISTIC BRAINS
To directly test SEMA5A expression in brains from autistic patients, tissue samples from 20 
cases with a primary diagnosis of autism and 10 controls were obtained through the Autism 
Tissue Program and the Harvard Brain Bank. Samples were dissected from Brodmann area 
19 of the occipital lobe cortex, a region demonstrating differences between autism cases and 
controls in functional imaging studies, and subjected to quantitative PCR 8. SEMA5A 
expression, determined relative to MAP2 (neuron specific), was significantly lower in autism 
brains than controls after adjustment for the age at brain acquisition, post-mortem interval, 
and sex (P = 0.024, Figure 2).
CANDIDATE AND LINKAGE REGION ASSOCIATION
We also analyzed our data for association signals at candidate genes or regions with prior 
evidence of involvement in autism. Although there are few well-replicated associations of 
biological candidate genes, there are many rare genetic variants, diseases, and syndromes 
associated with autism. Most of these loci have not been systematically assessed to see 
whether common variation in the gene or region might contribute to autism. We assessed 
four categories of candidate loci: 1) genes with previous evidence for association with 
common variation, 2) genes implicated by rare variants leading to autism, 3) genes causing 
Mendelian diseases associated with autism, and 4) regions where microdeletion or 
microduplication syndromes are associated with autism. For each gene, we included all 
SNPs passing basic quality criteria within 2 kb of the transcript.
Overall, there were no compelling results in these sets (all P > 10−4), considering the 
number of SNPs tested, and only two regions met criteria for region-wide (only SNPs in that 
gene/region considered) or set-wide (e.g. all candidate regions in the set of common variant 
genes considered) significance by permutation-testing (Supplementary Table 5). MECP2 
(Rett syndrome) met criteria for region-wide association (P = 0.0071, 5 SNPs, 
Supplementary Table 5). Moreover, the Williams syndrome region was borderline for set-
wide significance (P = 0.051, Supplementary Table 5). One SNP in particular showed strong 
association (rs2267831, P = 0.00012, OR = 0.56) – as this was a rare SNP with 
undertransmission of the minor allele, we genotyped a subset of families and observed 
similar, slightly less significant distortion (OR=0.61). The SNP is located within 
GTF2IRD1, a transcription factor within the critical region for the Williams syndrome 
cognitive behavioral profile 9,10,11.
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There appears to be little overlap between the regions of strongest linkage and association in 
this study. A more detailed assessment of SNP and haplotype association in the most 
significant linkage regions did not yield common variation that could explain the evidence 
for linkage (Supplementary Table 6). This is an expected outcome if linkage signals arise 
from rare, high penetrance variation (for which the genotyping arrays do not offer an 
adequate proxy) while association is sensitive to common variation with lower penetrance 
(that cannot be detected by linkage). For example, a 0.3% variant that increases risk by 10-
fold would readily be picked up by this informative linkage scan, but would very likely not 
be assessed by the common SNPs on the Affymetrix 5.0 array; by contrast, the modest and 
protective impact of the 5% variant at the SEMA5A rs10513025 creates no detectable excess 
allele sharing among siblings but is strongly detected by association.
During review of this manuscript, another GWAS was published which identified significant 
association to SNPs on chromosome 5p14 12. While there was significant overlap between 
study samples, each of these scans contained a large set of unique families, so we sought to 
evaluate independent evidence of the top SNP (rs4307059) reported at 5p14. This SNP 
happens to be directly genotyped by both Affymetrix and Illumina platforms. We have a 
sizable number (n=796) of affected subjects with two parents genotyped (and of 
predominantly similar European background). However, we observed no support for 
association at this locus (T:U 354:335 in favor of the minor allele, a trend in the opposite 
direction as reported).
DISCUSSION
Autism genes have been difficult to identify, despite the high heritability of autism spectrum 
disorders. Up to 10% of autism cases may be due to rare sequence and gene dosage variants, 
for example, mutations in NRXN1, NLGN3/4X, SHANK3, and copy number variants at 
15q11–q13 and 16p11.2. A number of diseases of known etiology, including Rett syndrome, 
fragile X syndrome, neurofibromatosis type I, tuberous sclerosis, Potocki-Lupski syndrome, 
and Smith-Lemli-Opitz syndrome are also associated with autism 1,13. However, the 
remaining 90% of autism spectrum disorders, while highly familial, have unknown genetic 
etiology. A genome-wide linkage study using the Affymetrix 10K SNP array to genotype 
over 1,000 families found no genome-wide significant linkage signals, but documented 
suggestive linkage at 11p12–p13 and 15q23–q25 and reinforced a modest role for rare copy-
number variants 14.
Many complex diseases have recently had great success with GWAS approaches, but most 
identified modest effects with odds ratios less than 1.3 (http://www.genome.gov/26525384). 
Our association analysis has excellent statistical power (>80%) to find effects of relatively 
common alleles (0.01–0.25 in frequency) explaining 1% of the variance in autism at the 
genome-wide significant level. It is near-perfectly powered for alleles down to 1% at the 
replication cut-off P < 10−4, assuming additive background genetic variance of 0.8 and 
shared environmental variance of 0.05 with prevalence of 0.006. One of the advantages of a 
family-based association test is that we avoid false positive results generated by population 
stratification, and in addition, we have performed careful quality control to reduce the 
chances of being misled by technical artifacts. However, the SNP coverage of the 
Weiss et al. Page 6
Nature. Author manuscript; available in PMC 2010 April 08.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Affymetrix 5.0 chips is incomplete; in fact, a recent resequencing survey suggests that these 
arrays assay only 57% of variants with MAF > 5% at r2 = 0.8 15. We therefore cannot 
exclude untested variation of large effect in autism. The linkage analysis, assuming a fully 
informative marker in 800 sibpairs, should detect sibling allele sharing of at least 55.125% 
16.
Our linkage analysis revealed two novel regions of linkage, 6q27 (LOD = 2.94) and 20p13 
(LOD = 3.81), with the latter formally exceeding the threshold for genome-wide 
significance. There is some overlap between the more modest signals (LOD > 2 on chr15 
and chr17) and previously reported suggestive signals, but little overlap with the most 
promising regions of common SNP association. This suggests that the regions of the genome 
showing linkage may harbor rare variation, potentially with allelic heterogeneity across 
families, which would require re-sequencing to uncover, as has been demonstrated for the 
7q35 region17,18,19. Interestingly, several of these regions overlap with rare syndromes or 
genetic events known to be strong risk factors for autism. For example, an autism case with 
a translocation disrupting 15q25 has been reported, while the 17p region overlaps the Smith 
Magenis and Potocki-Lupski Syndrome region.
The initial TDT analysis of this large multiplex autism dataset, did not reveal any 
associations meeting criteria for genome-wide significance, suggesting that there are not 
many common loci of moderate to large effect size even in a highly heritable disorder like 
autism. Nevertheless, replication data in our study identified a novel locus with genome-
wide significant evidence for association to autism. In addition, several other SNPs in the 
region show similarly strong association (rs10513026, rs16883317). We ascertained a large 
replication sample from independent family studies with a replication at P = 0.0061 and 
meta-analysis showed this association (P = 2.12 × 10−7) to meet criteria for genome-wide 
association in our experiment. This region on chromosome 5 harbors the gene encoding the 
bitter taste receptor, TAS2R1, and several uncharacterized ESTs and is adjacent to SEMA5A, 
a member of the semaphorin axonal guidance protein family, which has shown down-
regulated expression in transformed B lymphocytes from autism samples15. We have 
further extended this finding by directly demonstrating lowered SEMA5A gene expression in 
autism brain tissue. This is an attractive candidate gene given that its protein is a 
bifunctional guidance molecule, which is both attractive and inhibitory for developing 
neurons. Interestingly, the SEMA5A receptor is plexin B3, which also signals through the 
tyrosine kinase MET, a previously reported autism susceptibility gene20,21.
Finally, we investigated whether different classes of genes or regions -- loci previously 
implicated by functional or positional candidate gene association studies, rare variants 
implicated in autism, Mendelian disorder genes with association to autism, or regions of 
copy number variation associated with autism -- showed association with common alleles 
included in our marker set. Although there were several nominally significant associations, 
only the Williams syndrome region (one SNP in GTF2IRD1) was borderline statistically 
significant (P = 0.051), after correcting for the microdeletion/duplication syndrome regions 
tested. In the category of Mendelian disorders associated with autism, MECP2, the gene for 
Rett syndrome, showed region-wise statistical significance. These results raise the 
possibility that Rett and Williams syndrome genes may contribute more generally to autism 
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spectrum disorders. Although the genes in which common variation has been reported to be 
associated with autism do not show evidence for association, this cannot be interpreted as 
failure to replicate previous results in all cases, because much of the variation reported as 
associated is not captured on the Affymetrix platform (e.g. length polymorphisms, 
microsatellites, untagged SNPs such as the promoter variant at MET21). Instead, despite a 
high density of markers, our results suggest that we did not identify additional common 
variation with evidence for association. Overall however, our results imply that these 
postulated candidate regions, mostly based on rare events known to cause autism, are not 
among the regions with common alleles having the strongest risk effects for autism.
Interestingly, both our linkage and association analyses, from the primary and replication 
analyses, suggest that low frequency (<0.05) minor alleles may be common in autism. 
Intriguingly, the linkage studies reveal low frequency susceptibility alleles whereas the 
association analyses have uncovered rare alleles with odds ratios less than 0.6 (the common 
alleles in the population associated with increased risk for autism). This can occur when the 
ancestral allele, that was previously neutral or beneficial, now has detrimental effects 
revealed by an evolutionarily recent environment, or when a pleiotropic function of the 
allele is selectively advantageous, or when this variation is hitchhiking on a shared 
haplotype with a distinct beneficial allele 22. However, it is worth noting that our study 
design of ascertaining multiplex families is not well-powered to identify loci under this 
genetic model of common major alleles associated with autism susceptibility.
In summary, we report genome-wide significant linkage as well as an association of 
common genetic variation with autism. Our results will require follow-up to identify the 
functional variation in the linkage and association regions that we report here and to probe 
the functions of the relatively unstudied transcripts implicated. These results could provide 
completely novel insight into the biology and pathogenesis of a common 
neurodevelopmental disorder.
METHODS SUMMARY
SAMPLES AND GENOTYPING
Our primary samples are from the AGRE and NIMH Repositories. Replication with 
Affymetrix technology included NIMH controls, families collected by members of the 
Autism Consortium, and families ascertained from Montreal. Replication with Sequenom 
technology included the Autism Genome Project, Finnish, and Iranian subsets of Autism 
Consortium investigator-collected families. Details of the ascertainment for each sample 
collection, genotyping, and quality control processes can be found in Methods.
LINKAGE AND ASSOCIATION ANALYSIS
The linkage analysis was conducted with a pruned autosomal SNP set [see Methods for 
details of marker selection] and chromosome X set (670 SNPs) using the cluster option in 
MERLIN/MINX (r2 < 0.1) 23, yielding 16,581 independent markers. We performed 
confirmatory analysis on non-overlapping datasets by selecting alternate SNPs.
Weiss et al. Page 8
Nature. Author manuscript; available in PMC 2010 April 08.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Association analysis was performed in PLINK24. The basic association test was a 
transmission disequilibrium test (TDT), and the extra cases vs. controls analysis was 
performed by allelic association, after excluding cases that were not well-matched to the 
controls, based on multi-dimensional scaling (λ < 1.1). Combining the TDT and case-control 
tests was performed using expected and observed allele counts by the formula: Zmeta = 
(ΣEXP − ΣOBS)/√ΣVAR. Meta-analysis of AGRE/NIMH and replication data was 
performed using the statistic (ZAGRE/NIMH+Zreplication)/√2. Gene-set analysis was performed 
in PLINK using the set-based TDT. Imputation-based association was performed in PLINK 
with the proxy-tdt command, using the HapMap CEU parent samples as the reference panel 
and information score >0.8. Haplotype analysis in the linkage regions was performed using 
5-SNP sliding windows, as implemented in PLINK hap-tdt. See Methods section for details 
of determination of genome-wide significance thresholds.
METHODS
PRIMARY STUDY SAMPLES
All samples used in this study arose from investigations approved by the individual and 
respective Institutional Review Boards in the USA and at international sites where relevant. 
Informed consent was obtained for all adult study participants; for children under age 18, 
both the consent of the parents or guardians and the assent of the child were obtained.
AGRE samples—The Autism Genetic Resource Exchange (AGRE) curates a collection of 
DNA and phenotypic data from multiplex families with autism spectrum disorder (ASD) 
available for genetic research 3. We genotyped individuals from 801 families, selecting 
those with at least one child meeting criteria for autism by the Autism Diagnostic Interview-
Revised (ADI-R) 25, while the second affected child had an AGRE classification of autism, 
broad spectrum (patterns of impairment along the spectrum of pervasive developmental 
disorders, including PDD-NOS and Asperger syndrome) or Not Quite Autism (NQA, 
individuals who are no more than one point away from meeting autism criteria on any or all 
of the social, communication, and/or behavior domains and meet criteria for “age of onset”; 
or, individuals who meet criteria on all domains, but do not meet criteria for the “age of 
onset”). We excluded probands with widely discrepant classifications of affection status via 
the ADI-R and ADOS that could not be reconciled. We also excluded families with known 
chromosomal abnormalities (where karyotyping was available), and those with 
inconsistencies in genetic data (generating excess Mendelian segregation errors or showing 
genotyping failure on a test panel of 24 SNPs used to check gender and sample identity with 
the full array data). The self-reported race/ethnicity of these samples is 69% white, 12% 
Hispanic/Latino, 10% unknown, 5% mixed, 2.5% each Asian and African American, less 
than 1% Native Hawaiian/Pacific Islander and American Indian/Native Alaskan.
NIMH samples—The NIMH Autism Genetics Initiative maintains a collection of DNA 
from multiplex and simplex families with ASD. We genotyped individuals from 341 nuclear 
families, 258 of which were independent of the AGRE dataset, with at least one child 
meeting criteria for autism by the ADI-R, and a second child considered affected using the 
same criteria as described for the AGRE dataset above. Similar exclusion criteria were used, 
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including known chromosomal abnormalities and excess non-Mendelian inheritance. The 
self-reported race/ethnicity of these samples is 83% white, 4% Hispanic, 2% unknown, 7% 
mixed, 3% Asian, and 1% African American.
Merged dataset for primary screening—We utilized the Birdseed algorithm for 
genotype calling at both genotyping centers26,27. As 324 individuals were genotyped at 
both centers, we performed a concordance check. One sample showed substantial 
differences between the two centers, but no excess of Mendelian errors, indicating that a 
sample mix-up occurred in which each center genotyped a different sibling that was 
identified as the same sample. Excluding this sample, overall genotype concordance 
between the two centers was 99.72%.
Before merging data, we examined the distribution of chi-square values and used a series of 
quality control (QC) filters designed to identify a robust set of SNPs. We discovered that 
filtering AGRE genotypes to 98% completeness and less than 10 MEs was sufficient to 
remove SNPs that artificially inflated the chi-square distribution for SNPs with MAF (minor 
allele frequency) > 0.05. For MAF < 0.05, we observed much greater inflation (λ = 1.17), 
due entirely to a strong excess of SNPs with under-transmission of the minor allele (OR < 
1). While the same filters yielded high-quality results for SNPs with over-transmission of 
the minor allele (λ = 1.04), we found that much stricter filtering was required for rarer SNPs 
with OR<1 (missing data < .005). This is not unexpected based on a well-documented bias 
in the TDT: if missing data are preferentially biased against heterozygotes or rare 
homozygotes, significant, artificial over-transmission of the common allele is expected 
28,29. To achieve comparable quality for the NIMH dataset, we filtered on 96% 
completeness and fewer than 4 MEs. Our final QQ plot for the combined dataset is shown in 
Supplementary Figure 1 and has a λ ~ 1.03, less than that observed in the Wellcome Trust 
Case Control Consortium paper for five of the seven phenotypes studied 30. The combined 
data set, consisting of 1,031 families (856 with two parents) and a total of 1,553 affected 
offspring, was employed for association testing.
For linkage analyses, the combined AGRE/NIMH dataset was further merged with Illumina 
550K genotype data generated at the Children’s Hospital of Philadelphia (CHOP) and 
available from AGRE, adding ~300 nuclear families (1,499 samples). We used the extensive 
overlap of samples between the AGRE/NIMH and the CHOP datasets (2,282 samples) to 
select an extremely high quality set of SNPs for linkage analysis. Specifically, we required 
SNPs to be on both the Affymetrix 500K/5.0 and Illumina 550K platforms, with >99.5% 
concordance across platforms. We further restricted SNPs to MAF > 0.2, < 1% missing data, 
Hardy Weinberg P> 0.01, and no more than 1 ME. This left ~36,000 SNPs of outstanding 
quality. For autosomal SNPs, we further pruned using PLINK to remove SNPs with r2 > 0.1, 
yielding 16,311 SNPs.
REPLICATION SAMPLES
NIMH control samples—Controls obtained from the NIMH Genetics Repository were 
genotyped on the Affymetrix 500K platform at the Broad Institute Genetic Analysis 
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Platform for another study 6. Of these, 1,494 matched well with our sample, and were used 
as controls to compare with the cases and parents in our study.
Montreal samples—Subjects diagnosed with autism spectrum disorders with both of their 
parents were recruited from clinics specializing in the diagnosis of Pervasive Developmental 
Disorders (PDD), readaptation centers, and specialized schools in the Montreal and Quebec 
City regions, Canada, as described 31. Subjects with ASD were diagnosed by child 
psychiatrists and psychologists expert in the evaluation of ASD. Evaluation based on the 
Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria included the use of 
the Autism Diagnostic Interview-Revised (ADI-R)25 and the Autism Diagnostic 
Observation Schedule (ADOS)32. As an additional screening tool for the diagnosis of ASD, 
the Autism Screening Questionnaire, which is derived from the ADI-R, was completed 33. 
Furthermore, all proband medical charts were reviewed by a child psychiatrist expert in 
PDD to confirm their diagnosis and exclude subjects with any co-morbid disorders. 
Exclusion criteria were: (1) an estimated mental age < 18 months, (2) a diagnosis of Rett 
syndrome or Childhood Disintegrative Disorder and (3) evidence of any psychiatric and 
neurological conditions including: birth anoxia, rubella during pregnancy, fragile X 
syndrome, encephalitis, phenylketonuria, tuberous sclerosis, Tourette and West syndromes. 
Subjects with these conditions were excluded based on parental interview and chart review. 
However, participants with a co-occurring diagnosis of semantic-pragmatic disorder (due to 
its large overlap with PDD), attention deficit hyperactivity disorder (seen in a large number 
of patients with ASD during development), and idiopathic epilepsy (related to the core 
syndrome of ASD) were eligible for the study.
Santangelo EDSP family samples—Families were ascertained for having one or more 
autistic children and at least one non-autistic child aged 16 or older for an extremely 
discordant sib-pair linkage study. Recruitment took place in Massachusetts and surrounding 
states through contacts with parent support and patient advocacy groups, brochures, 
newsletters, and the study web site. Parents were interviewed about their children, and non-
autistic children were interviewed about themselves. An informant/caregiver, usually the 
proband’s mother, was interviewed using the Autism Diagnostic Instrument-Revised (ADI-
R) to confirm the diagnosis of autism at age 4–5 years25,34. Families were included if the 
affected children met Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) 
criteria for autistic disorder and their non-autistic siblings (aged 16 and older) did not 
display any of the broader autism phenotype traits, which were assessed with the (M-PAS-
R), the Pragmatic Language Scale (PLS), and the Friendship Interview 35,36. Probands 
were excluded if they had medical conditions associated with autism such as fragile X 
syndrome or gross CNS injury, or if they were under four years of age, due to the possible 
uncertainty in diagnosis at younger ages. Twenty-nine families met eligibility criteria for the 
study and comprised the final sample for analysis.
High Functioning Autism family samples—Families were included if their affected 
child had been previously diagnosed with Autism or Asperger syndrome, had a level of 
intellectual functioning above the range of mental retardation (i.e., Full Scale, Verbal, and 
Performance IQ > 70), chronological age between 6 and 21 years, and an absence of 
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significant medical or neurological disorders (including fragile X syndrome and tuberous 
sclerosis). Families were ascertained and recruited through the Acute Residential Treatment 
(ART) programs and outpatient child and adolescent services at McLean Hospital, as well as 
through associated hospitals and clinics. Brochures and a website were also utilized. Thirty-
three families (133 participants) were enrolled in the study. Participation was voluntary.
MGH-Finnish collaborative samples—Altogether 58 individuals with a diagnosis of 
High Functioning Autism (HFA) or Asperger’s Syndrome (AS) were recruited in Finland. 
Fifty-two children and adolescents aged 8 to 15 years were identified from patient-records at 
the Oulu University Hospital in 2003. These children and adolescents have been evaluated 
for HFA/AS at the Oulu University Hospital. In addition, six children (3 boys, 3 girls) 11 
years of age were recruited from an epidemiological study conducted in 2001 37.
All participants had full scale IQ scores greater than or equal to 80 measured with the 
Wechsler Intelligence Scale for Children—Third Revision 38. Furthermore, none of the 
children subjects were diagnosed with other developmental disorders (e.g., dysphasia, 
fragile X syndrome). Clinical diagnoses of HFA/AS were confirmed by administering the 
Autism Diagnostic Interview-Revised 25 and the Autism Diagnostic Observation Schedule 
32. Of the 58 participants with HFA/AS, 35 met the diagnostic criteria for AS and 21 met 
the diagnostic criteria for HFA according to ICD-10 diagnostic criteria 39. Two participants 
met diagnostic criteria for PDD-NOS; these participants were excluded due to their 
manifesting different and less severe symptoms than our sample of children with HFA or 
AS.
Children’s Hospital Boston samples—Probands with a documented history of clinical 
diagnosis of ASD were recruited at Children’s Hospital Boston. To participate, they had to 
be over 24 months of age and have at least one biological parent or an affected sibling 
available. Subjects were excluded if they had an underlying metabolic disorder or any 
chronic systemic disease, an acquired developmental disability (e.g. birth asphyxia, trauma-
related injury, meningitis, etc.), or cerebral palsy. All participants provided informed 
consent and a phenotyping battery was performed including the Autism Diagnostic 
Observation Schedule (ADOS), the Autism Diagnostic Interview- Revised (ADI-R) and 
other measures to assess cognitive status. 75% of subjects with a clinical diagnosis met strict 
research criteria for ASD on both ADI-R and ADOS. In addition, a complete family and 
medical history was obtained.
Homozygosity Mapping Collaborative for Autism (HMCA) samples—Families 
with cousin marriages and children affected by autism spectrum disorder (ASD) with or 
without mental retardation (MR) were recruited by multiple collaborators in the HMCA. The 
patients from Istanbul were evaluated by a child psychiatrist (Nahit M. Mukaddes) trained in 
the Autism Diagnostic Observation Schedule (ADOS) and Autism Diagnostic Interview - 
Revised (ADI-R), and who made diagnoses according to DSM-IV-TR criteria and the 
Childhood Autism Rating Scale (CARS). Patients from Kuwait were enrolled from the 
Kuwait Centre for Autism by Samira Al-Saad. In Jeddah, Saudi Arabia, patients were 
evaluated by both a developmental pediatrician (Soher Balkhy) and a pediatric neurologist 
(Generoso Gascon) and diagnoses were based on DSM-IV-TR criteria. In Lahore, Pakistan, 
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a neurologist (Asif Hashmi) with training in the ADOS and ADI-R diagnosed patients using 
DSM-IV-TR criteria. In most settings, patients were enrolled from tertiary clinical centers 
and these patients had standard of care neuromedical assessments, including physical 
examination, medical and neurological history, fragile X testing, and other genetic and 
metabolic testing when indicated. MRI was obtained for patients in whom a brain 
malformation was suspected or seizures were present. In addition, IQ scores (usually from 
the Stanford-Binet) and adaptive behavior measures were obtained from the patients’ 
existing medical records. Secondary assessments were conducted on the most informative 
pedigrees by the Boston clinical team in collaboration with local multi-disciplinary teams. 
Clinical members of the Boston team included: developmental psychologists (Janice Ware, 
Elaine LeClaire, Robert M. Joseph), pediatric neurologists (Ganesh H. Mochida, Anna 
Poduri), a clinical geneticist (Wen-Han Tan), and a neuropsychiatrist (Eric M. Morrow). The 
secondary assessment battery was designed to obtain a comprehensive description of current 
and historical autism symptomatology, cognitive and adaptive functioning, and neurological 
and physical morphological status in the patient and pedigree. The secondary assessment 
included: neurologic examination; genetic dysmorphology examination; the CARS; the 
Social Communication Questionnaire (SCQ) administered with probing on par with the 
ADI-R by ADI-R reliable examiners; the ADOS (usually Module 1); the Vineland Adaptive 
Behavior Scales, Second Edition (VABS-II); Kaufman Brief Intelligence Test, Second 
Edition (KBIT-II). ADOS assessments were videotaped and dysmorphology findings were 
photographed for archival purposes.
AGP samples—Individuals typically received at least two of three evaluations for autism 
symptoms: ADI-R, ADOS and clinical evaluation. Of the 1,679 affected individuals from 
1,443 families, 966 met criterion for autism on the ADI-R and ADOS and most of these also 
had a clinical evaluation of autism; 160 affected individuals met criteria for autism on one of 
the two diagnostic instruments (ADI-R, ADOS) but were missing information on the other 
instrument; and, 553 individuals met criteria for spectrum disorder on one or both 
instruments. Affected individuals were recruited from both simplex and multiplex families, 
71% of this sample being from multiplex families. The majority of the families were of 
European ancestry (83%).
Finnish autism family samples—Families were recruited through university and 
central hospitals. Detailed clinical and medical examinations were performed by 
experienced child neurologists as described elsewhere40. Diagnoses were based on ICD-10 
39 and DSM-IV 41 diagnostic nomenclatures. Families with known associated medical 
conditions or chromosomal abnormalities were excluded from the study. A total of 106 
families included 400 individuals for whom genotype data was available. Of these, 111 had 
a diagnosis of infantile autism and 13 a diagnosis of Asperger syndrome. All families were 
Finnish, except for one family where the father was Turkish.
Iranian Trio samples—Eligible participants in this study were Iranian families with at 
least one child affected with ASD, including cases of autistic disorder, Asperger syndrome 
and pervasive developmental disorder-not otherwise specified (PDD-NOS). Eighty families 
(282 individuals) from Iran were ascertained and assessed. This sample was ascertained by 
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screening and diagnostic testing of over 90,000 preschool children from Tehran in 2004. 
Diagnoses of children were made according to DSM-IV criteria via the ADI-R and the 
ADOS. Patients with abnormal karyotypes and dysmorphic features were excluded. Most of 
the families were father-mother-child trios but some had more than one affected child. All 
affected biological siblings were assessed with the same diagnostic tools. We have 
ascertained and assessed 80 families (282 individuals) from Iran.
AFFYMETRIX GENOTYPING
The AGRE samples were genotyped on Affymetrix 5.0 chips at the Genetic Analysis 
Platform of the Broad Institute, using standard protocols. The 5.0 chip was designed to 
genotype nearly 500,000 SNPs across the genome in order to enable genome-wide 
association studies 26,27. The NIMH controls were genotyped at the Broad Institute using 
the Affymetrix 500K Sty and Nsp chips, using a similar protocol 6. The Autism Consortium 
and Montreal replication samples were also genotyped at the Broad Institute under the same 
conditions. The NIMH autism samples were genotyped at the Johns Hopkins Center for 
Complex Disease on the Affymetrix 500K (Nsp and Sty) and 5.0 platforms using similar 
standard protocols.
Genotype calling for the 5.0 arrays was performed by Birdseed 26,27 and for the 500K 
arrays was performed by BRLMM. As basic QC filters for the data generated at the Broad 
Institute, we required that genotyping was >95% complete for each individual, and that each 
family had fewer than 10,000 Mendelian inheritance errors across the genome. We also 
required that each SNP had >95% genotyping, fewer than 15 Mendelian errors, Hardy-
Weinberg Equilibrium P > 10−10, and minor allele frequency greater than 1%. For the 
AGRE sample, this left 2,883 high quality individuals genotyped for 399,147 SNPs with 
99.6% average call rate. The basic filters for the data generated at Johns Hopkins were 
individual call rates > 95% for 5.0 arrays and > 90% for 500K arrays data, fewer than 5,000 
Mendelian errors per family. Only monomorphic SNPs and those with greater than 50% 
missing data were dropped, for 498,216 SNPs. Our combined dataset had nearly 365,000 
SNPs passing QC.
SEQUENOM GENOTYPING
SNPs were assayed using Sequenom technology for the AGP samples at three centers, 
namely Gulbenkian, Mt. Sinai, and Oxford: DNA from 1,629 families representing 
numerous recruiting sites was genotyped for 54 SNPs. SNPs with >3% missing data, namely 
rs4690464, rs10513025, and rs17088296, were excluded from analysis. The next step in our 
quality control process was to remove families with ≥4 Mendelian errors, out of 51 
remaining loci, under the assumption that this indicated pedigree errors. Data from 110 
families were removed due to Mendelian errors. Thereafter, SNPs were removed if they 
showed excessive Mendelian errors (>16) in the remaining families. Using this criterion, 
two more SNPs, rs155437 and rs1925058, were removed from analysis. It was apparent that 
DNA quality varied by study site and could be responsible for concomitant genotype quality 
differences. Therefore, we also evaluated rate of missing genotypes per locus and study site. 
Our analyses showed that DNA from a few population samples showed excess missingness 
for two SNPs, rs4742408 and rs7869239, relative to the remaining population samples. 
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Specifically three population samples showed more than 7% missing genotypes for 
rs4742408 and rs7869239 whereas the remaining population samples had about 1% or less 
missing genotypes. Therefore, for these loci we deleted genotypes only from the samples 
showing excess missingness. As a final quality control step, we then evaluated missing 
genotypes for the remaining loci. If more than five loci were missing genotypes, the 
individual’s data was removed from analysis. By this criterion 76 additional families became 
uninformative for family-based association analysis, leaving 1,443 families for association 
analysis. The Finnish autism samples were genotyped in the Peltonen lab, and the Iranian 
trios were genotyped at the Broad Institute using very similar protocols. All samples were 
genotyped using aliquots from the same pooled primers and probes.
COPY NUMBER ANALYSIS
Because of previous reports of two large (>1 Mb), independent de novo deletions spanning 
this locus 42, we assessed the region surrounding rs10513025 and the entire SEMA5A locus 
for copy number variation that could either explain or provide independent evidence of the 
importance of this region to autism using Birdsuite 26 to analyze all Affymetrix 5.0 samples. 
Birdsuite genotypes previously annotated common copy number polymorphisms 27 and in 
parallel searches for novel copy number variants using an HMM. Probe coverage in the 
region was good, with no 50kb window having fewer than 10 probes and an average spacing 
between probes of 2.5 kb, allowing very good sensitivity for CNVs greater than 25kb. We 
found no deletions or duplications near this SNP, nor any overlapping the gene SEMA5A. 
The closest copy number variants upstream and downstream of this SNP appeared to be a 
rare (~2–3% frequency, previously annotated CNP) 40kb deletion from 288 kb from the 3′ 
end of SEMA5A, and a rare (~1% frequency, novel) 20kb deletion 356 kb upstream of the 5′ 
end of SEMA5A. Each of these appeared to be segregating polymorphisms, but fall far 
outside of the boundaries of SEMA5A and TAS2R1 and far beyond the linkage 
disequilibrium block containing rs10513025.
EXPRESSION ANALYSIS
Fresh-frozen brain tissue samples dissected from the cortex (Brodmann area 19) were 
obtained through the Autism Tissue Program (www.atpportal.org) from the Harvard Brain 
Bank and the NICHD Brain and Tissue Bank at the University of Maryland from 20 samples 
with a primary diagnosis of autism, and 10 controls. Total RNA was extracted using TRIzol 
reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. 
Complementary DNA (cDNA) was generated from 8μg of total RNA using the Superscript 
III First-Strand Synthesis kit (Invitrogen). cDNA was diluted 1:5 in 10mM Tris and 1μL of 
diluted cDNA was used per 10μL PCR reaction. Quantitative real-time PCR was performed 
on a Lightcycler 480 (Roche Applied Science, Indianapolis, IN) using 2X Taqman Gene 
Expression Master Mix and probes obtained from Applied Biosystems (ABI, Foster City, 
CA): SEMA5A (Hs01549381_m1), MAP2 (Hs01103234_g1), TBP (Hs00920497_m1), 
GAPDH (4333764F). For multiplex reactions, 0.5μL FAM-labeled SEMA5A probe and 
0.5μL VIC-labeled MAP2 probe were used per 10μL reaction. The amount of SEMA5A 
relative to MAP2 was determined for each case using the ΔΔCt method 43. Comparison of 
SEMA5A to TBP and GAPDH yielded similar results. Logistic regression was performed on 
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autism status, adjusting for age at death, post-mortem interval, sex, and SEMA5A expression, 
with a 1-sided P-value reported for the association of lower SEMA5A expression with autism 
status.
DETERMINATION OF SIGNIFICANCE
To determine an appropriate experimental threshold for genome-wide significance, 
permutation was performed on this dataset by gene-dropping, and genome-wide significance 
was estimated by taking the lowest P-value from each of 1000 permuted datasets and using 
the 50th as a threshold for P < 0.05 experiment-wide significance (P<2.5 × 10−7). To 
calculate an estimate of the effective number of tests (Teff), we used the following 
algorithm:
1. Start with the most 5′ SNP on a chromosome (SNPi,j),where i=chromosome, and 
j=SNP position, and calculate pairwise LD with all downstream SNPs within 1 Mb 
(r2[SNP1,1 × SNP1,n])
2. For SNP1,1, Teff(1,1)=1-max(r2[SNP1,1 × SNP1,n])
3.
For chromosome i, , where m=the total number of SNPs on a 
chromosome
4.
Since this algorithm only accounts for pair-wise LD, it provides a conservative estimate of 
the number of effective tests.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Genome-wide Linkage Results.
The genome-wide linkage results are shown in 1a, with the orange line indicating LOD 3. 
The four chromosomes with LOD > 2 are shown in 1b. The black and blue lines indicate 
results from families with both parents genotyped and all families, respectively. The green 
line indicates information content. The red circle indicates the position of the centromere.
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Figure 2. 
SEMA5A Expression in Autism Brains
SEMA5A gene expression is shown relative to MAP2. Yellow diamonds indicate individual 
expression levels for each sample; error bars indicate standard error (SE).
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